Philippines Biopsy Devices Market Estimated to Exceed US$ 93.17 Million By 2034: IMARC Group

Philippines Biopsy Devices Market Overview

According to IMARC Group's latest research report, the Philippines biopsy devices market reached a value of USD 58.92 Million in 2025. Looking forward, the market is projected to reach USD 93.17 Million by 2034, growing at a CAGR of 5.22% during 2026-2034. The market is driven by government healthcare reforms under the Universal Health Care Act and the National Integrated Cancer Control Act strengthening cancer screening and early detection, nearly 189,000 new cancer cases reported nationally with four Filipinos dying of cancer every hour, PhilHealth's expanded outpatient cancer screening coverage under the YAKAP program, the establishment of the Pharma-Med Development Hub to attract medical device manufacturers, and the integration of AI-powered diagnostic technologies across healthcare facilities.

Get a sample copy of this report: https://www.imarcgroup.com/philippines-biopsy-devices-market/requestsample

Philippines Biopsy Devices Market Summary

• Cancer remains one of the leading causes of death in the Philippines, with approximately 189,000 new cases and over 113,000 deaths reported. The disease impacts 189 out of every 100,000 Filipinos, translating to roughly 96 cancer deaths per day. Lung, breast, liver, and colorectal cancers rank among the most common and most fatal, driving sustained demand for tissue biopsy as a critical step in accurate diagnosis and treatment planning across the country's healthcare system.

• The Philippine government enacted the Universal Health Care Act (Republic Act No. 11223), automatically enrolling all Filipino citizens in the National Health Insurance Program. This legislation, combined with the National Integrated Cancer Control Act, has laid the groundwork for expanding access to cancer screening, detection, and treatment services. The law mandated the creation of a Cancer Assistance Fund and the National Integrated Cancer Control Council, significantly broadening the scope of publicly funded cancer diagnostics.

• PhilHealth launched the YAKAP program, expanding coverage to include free outpatient cancer screening tests for breast, lung, liver, and colorectal cancers. Benefits include mammograms valued at PHP 2,160, breast ultrasounds at PHP 1,350, and low-dose CT scans, along with free medical consultations and annual medicines worth up to PHP 20,000. This expanded coverage directly drives demand for follow-up biopsy procedures when screening identifies suspicious findings.

• Needle biopsy procedures are gaining preference across Philippine healthcare facilities due to their minimally invasive nature, reduced patient discomfort, faster recovery times, and lower procedural costs compared to surgical biopsies. Core needle biopsy and fine needle aspiration techniques provide high-accuracy tissue sampling through outpatient procedures, aligning with the healthcare system's objectives of improving patient throughput and delivering cost-effective diagnostic services in resource-constrained settings.

• Breast cancer presents a particularly pressing challenge in the Philippines, with high incidence rates among younger Filipino women who are often diagnosed earlier than their counterparts in other Asian countries. Many patients continue to be diagnosed at later stages due to limited access to screening programs, underscoring the need for expanded biopsy services. PhilHealth's Z Benefit Package now covers Stages 0 to 4 of breast cancer, up from the previous Stage 0 to IIIA limit, with coverage increasing by PHP 1.4 million per patient.

• The Philippines medical device and pharmaceutical market reached USD 51.6 billion, with 99.2% of medical devices supplied internationally. Private hospital groups have announced combined capital investments exceeding USD 500 million for new hospitals and facility upgrades. Healthcare spending reached PHP 1.20 trillion, with 44.8% from government financing schemes, creating a growing procurement base for advanced biopsy guidance systems, needles, and associated diagnostic equipment.

• Hospitals and clinics serve as the dominant end-user segment, housing the imaging infrastructure, procedural suites, and specialist expertise required for biopsy procedures. The Department of Health's 2024-2028 Strategic Framework for the National Integrated Cancer Control Program emphasizes strengthening primary healthcare and establishing Cancer Specialty Centers, expanding the institutional base where biopsy procedures can be performed across the Philippines.

• Luzon commands the largest share of the biopsy devices market, reflecting the concentration of major cancer treatment centers, teaching hospitals, and specialist diagnostic facilities in Metro Manila and surrounding provinces. Visayas and Mindanao represent growing markets as government investments in regional healthcare infrastructure and the designation of Cancer Specialty Centers expand diagnostic capabilities beyond the national capital region.

Key Trends Shaping the Philippines Biopsy Devices Market

• AI-powered diagnostic imaging systems are increasingly being adopted across Philippine healthcare facilities, using advanced machine learning to streamline diagnostic workflows. These systems incorporate powerful reconstruction engines and intelligent processing tools that enhance image quality and reduce scan times by up to three times while maintaining high resolution, enabling faster and more accurate identification of biopsy targets in cancer screening programs.

• The establishment of the Pharma-Med Development Hub through a partnership between the Philippine FDA and PEZA is attracting medical device manufacturers with tax incentives and streamlined regulatory approvals. This initiative aims to reduce the country's heavy import dependency for medical devices and stimulate domestic production capabilities, potentially lowering biopsy device costs and improving supply chain reliability for healthcare facilities.

• Virtual assistants, chatbots, and AI-supported clinical tools are playing an increasingly important role in Philippine healthcare, helping to ease workloads, support decision-making, and strengthen patient management in facilities facing healthcare worker shortages. For biopsy procedures specifically, AI-guided imaging improves the accuracy of tissue sampling by identifying ideal biopsy sites, minimizing procedure time, and enhancing sample quality.

• The convergence of telemedicine and telepathology is creating new diagnostic opportunities in the Philippines, enabling remote areas to connect with specialist pathologists who can support biopsy interpretation and consultation. This technology is particularly valuable given the shortage of radiologists, pathologists, and trained technicians in rural settings, helping bridge the geographic gap in cancer diagnostic services across the archipelago.

• Minimally invasive biopsy techniques are gaining significant traction, with vacuum-assisted biopsy devices, ultrasound-guided procedures, and stereotactic-guided biopsy systems being adopted at tertiary hospitals and cancer centers. These technologies improve tissue sampling accuracy while reducing patient discomfort and recovery time, aligning with the broader shift toward outpatient diagnostic services and cost-effective healthcare delivery models.

Explore the full report with TOC & list of figures: https://www.imarcgroup.com/philippines-biopsy-devices-market

Market Growth Factors

Government Healthcare Reforms and Expanded Cancer Screening Programs

The Philippine government's comprehensive healthcare reforms are creating a strong foundation for biopsy device demand. The Universal Health Care Act automatically enrolled all Filipino citizens in the National Health Insurance Program, while the National Integrated Cancer Control Act established the institutional framework for strengthening cancer screening and early detection services. The 2024-2028 Strategic Framework for the National Integrated Cancer Control Program emphasizes building capacity in primary care facilities and Cancer Specialty Centers for prevention, screening, and early diagnosis. PhilHealth's YAKAP program now covers outpatient cancer screening tests for breast, lung, liver, and colorectal cancers, with specific benefit amounts for mammograms, breast ultrasounds, and CT scans. The Z Benefit Package has been expanded to cover all stages of breast cancer from Stage 0 to Stage 4. Cancer-related premature deaths cost the Philippine economy approximately PHP 35.3 billion annually, and early identification can boost survival rates up to 99% for breast cancer and over 90% for cervical cancer, providing a compelling economic and clinical rationale for expanded screening that directly drives biopsy device demand.

Rising Cancer Burden and Demographic Shifts Intensifying Diagnostic Need

The Philippines faces a steadily intensifying cancer burden that is reshaping healthcare priorities and increasing the need for advanced biopsy devices. Approximately 189,000 new cancer cases are reported nationally, with over 113,000 cancer-related deaths, meaning roughly four Filipinos die of cancer every hour. Lung, breast, liver, and colorectal cancers consistently rank among the most common and most fatal diagnoses. Breast cancer presents a particular concern, with Filipino women often diagnosed at younger ages compared to counterparts in other Asian countries. Many patients continue to be diagnosed at later stages due to limited screening access, highlighting persistent gaps in early detection infrastructure. The country's rapidly aging population is expected to place sustained pressure on the healthcare system as age-related cancers become more prevalent. Ischemic heart disease accounts for 20.2% of total deaths, further highlighting the demand for cardiovascular-related diagnostic devices. As urbanization, lifestyle changes, and rising health awareness expand screening demand, healthcare providers are investing in modern biopsy technologies to support timely and accurate tissue analysis across hospitals, clinics, and diagnostic centers nationwide.

Healthcare Infrastructure Investment and Medical Device Market Expansion

Significant investments in healthcare infrastructure are strengthening the Philippines' capacity to adopt advanced biopsy technologies. The total healthcare expenditure reached PHP 1.20 trillion, with 44.8% coming from government financing schemes, reflecting a strong public commitment to healthcare development. Private hospital groups announced combined capital investments exceeding USD 500 million for new hospitals and facility upgrades, focusing on advanced diagnostic equipment and international patient services. The Philippines medical device and pharmaceutical market reached USD 51.6 billion and is projected to reach USD 94.4 billion by 2034. The establishment of the Pharma-Med Development Hub through a Philippine FDA and PEZA partnership offers tax incentives and faster regulatory pathways to attract medical device manufacturers, research organizations, and clinical testing firms. This initiative is designed to reduce the country's 99.2% import dependency for medical devices while stimulating domestic production capabilities. The Department of Health's strategic framework calls for expanding Cancer Specialty Centers within the national health facility plan, creating new institutional demand for biopsy guidance systems, needles, forceps, and associated diagnostic equipment across the Philippine healthcare system.

Philippines Biopsy Devices Market Segmentation

IMARC Group provides an analysis of the key trends in each segment of the Philippines biopsy devices market, along with forecasts at the country and regional levels from 2026-2034. The market has been categorized based on procedure type, product, application, guidance technique, and end user.

By Procedure Type:

• Surgical Biopsy

• Needle Biopsy

By Product:

• Biopsy Guidance Systems

• Needle Based Biopsy Guns

• Biopsy Needles

• Biopsy Forceps

• Others

By Application:

• Breast Biopsy

• Lung Biopsy

• Colorectal Biopsy

• Prostate Biopsy

• Others

By Guidance Technique:

• Ultrasound-guided Biopsy

• Stereotactic-guided Biopsy

• MRI-guided Biopsy

• Others

By End User:

• Hospitals and Clinics

• Academic and Research Institutes

• Others

By Region:

• Luzon

• Visayas

• Mindanao

Key Players in the Philippines Biopsy Devices Market

The Philippines biopsy devices market is characterized by a competitive landscape dominated by international medical technology companies with established distribution networks and strong brand recognition. Major global players including BD (Becton, Dickinson and Company), Hologic Inc., Medtronic, Cardinal Health, Boston Scientific Corporation, Olympus Corporation, and CONMED Corporation maintain strong market positions through comprehensive product portfolios spanning biopsy needles, guidance systems, and biopsy guns. Competition centers on product innovation, AI-guided imaging integration, regulatory compliance, and the ability to provide comprehensive after-sales support including training, maintenance, and technical assistance. Key competitive strategies include partnerships with local distributors, participation in medical conferences and continuing education programs, and alignment with government healthcare initiatives such as the Universal Health Care Act and the National Integrated Cancer Control Program. The market remains heavily import-dependent, with 99.2% of medical devices supplied internationally, though the Pharma-Med Development Hub established through the Philippine FDA and PEZA partnership may gradually shift competitive dynamics by encouraging local manufacturing partnerships.

Key Aspects Required for the Philippines Biopsy Devices Market Report

• Market Performance: An in-depth analysis of the Philippines biopsy devices market covering historical trends and current dynamics, with a focus on the USD 58.92 Million valuation and projected growth trajectory reaching USD 93.17 Million by 2034.

• Market Segmentation: Comprehensive breakdown across procedure types (surgical, needle), products (guidance systems, biopsy guns, needles, forceps), applications (breast, lung, colorectal, prostate), guidance techniques (ultrasound, stereotactic, MRI), and end users.

• Regional Analysis: Detailed evaluation of biopsy device demand across Luzon, Visayas, and Mindanao, covering cancer center distribution, diagnostic infrastructure availability, and healthcare investment patterns.

• Competitive Landscape: Profiling of major international players including BD, Hologic, Medtronic, Cardinal Health, Boston Scientific, Olympus, and CONMED, covering product portfolios, distribution strategies, and market positioning.

• Industry Trends and Drivers: Assessment of government healthcare reforms, rising cancer incidence, PhilHealth screening coverage expansion, AI-powered diagnostics adoption, and infrastructure investment driving market growth.

• Technology Analysis: Examination of image-guided biopsy systems (ultrasound, MRI, stereotactic), AI-assisted diagnostics, minimally invasive needle biopsy techniques, and telemedicine innovations transforming cancer diagnostics.

• Regulatory and Policy Analysis: Evaluation of the Universal Health Care Act, National Integrated Cancer Control Act, PhilHealth YAKAP program, Pharma-Med Development Hub, and FDA regulatory pathways supporting biopsy device procurement.

• Future Outlook: Forward-looking projections covering the implications of expanded cancer screening programs, healthcare infrastructure investments, domestic manufacturing initiatives, and AI integration on long-term market expansion.

Recent News and Developments

• August 2024: PhilHealth launched expanded coverage for outpatient cancer screening tests under the YAKAP (Yaman ng Kalusugan) program, covering mammograms, breast ultrasounds, and low-dose CT scans for breast, lung, liver, and colorectal cancers, with benefits including free medical consultations and medicines worth up to PHP 20,000 annually.

• August 2024: The Philippine FDA and PEZA established the country's first Pharma-Med Development Hub to attract medical device manufacturers, research organizations, and clinical testing firms, offering tax incentives and streamlined regulatory approvals to stimulate domestic medical device production.

• March 2024: PhilHealth expanded its Z Benefit Package under Circular 2024-0007 to cover Stages 0 to 4 of breast cancer, up from the previous Stage 0 to IIIA limit, increasing coverage by PHP 1.4 million per patient for comprehensive breast cancer treatment including diagnostic biopsy procedures.

• February 2024: The Department of Health, in collaboration with the WHO, launched the 2024-2028 Strategic Framework for the National Integrated Cancer Control Program, strengthening primary healthcare as the foundation for equitable access to cancer screening and early detection services.

• 2025: Private hospital groups in the Philippines announced combined capital investments exceeding USD 500 million for new hospitals and facility upgrades focused on advanced diagnostic equipment and international patient services, expanding the institutional base for biopsy procedures.

• 2025: PhilHealth issued quality standards circulars for screening of lung cancer, liver cancer, colorectal cancer, and breast cancer to establish standardized reference protocols for cancer screening services across accredited healthcare facilities.

• 2024: Hologic Inc. launched a next-generation vacuum-assisted biopsy system with enhanced tissue sampling capabilities, improving diagnostic accuracy for breast biopsy procedures and setting new standards for minimally invasive tissue acquisition globally.

• 2025: The Philippines medical device and pharmaceutical market reached USD 51.6 billion, with healthcare spending at PHP 1.20 trillion including 44.8% from government financing, strengthening the procurement base for advanced diagnostic and biopsy equipment.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=44336&flag=C

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 611 7970
United States: +1-631-791-1145

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a great impact. The company provides a comprehensive suite of market entry and expansion services. IMARC's offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, and networking facilitation, among others.

The company has done projects in over 135 countries and has helped more than 2,500 clients across the globe. IMARC currently works from 11 offices across the world, including its headquarters in Noida, India. It has a team of over 600 people, including former industry executives, subject matter experts, and management professionals. IMARC is among the top 10 management consulting firms based in India.

This release was published on openPR.